The Costs of Preventing and Treating Chagas Disease in Colombia

被引:52
作者
Castillo-Riquelme, Marianela [1 ]
Guhl, Felipe [2 ]
Turriago, Brenda [2 ]
Pinto, Nestor [2 ]
Rosas, Fernando [3 ]
Martinez, Monica Florez [4 ]
Fox-Rushby, Julia [5 ]
Davies, Clive [6 ]
Campbell-Lendrum, Diarmid [6 ]
机构
[1] London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Econ & Financing Programme, London WC1, England
[2] Univ Los Andes, Dept Ciencias Biol, Fac Ciencias, Ctr Invest Microbiol & Parasitol Trop CIMPAT, Bogota, Colombia
[3] Fdn Clin Shaio, Bogota, Colombia
[4] Univ Ind Santander UIS, Ctr Invest Enfermedades Trop CINTROP, Piedecuesta, Santander, Colombia
[5] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England
[6] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1, England
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pntd.0000336
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The objective of this study is to report the costs of Chagas disease in Colombia, in terms of vector disease control programmes and the costs of providing care to chronic Chagas disease patients with cardiomyopathy. Methods: Data were collected from Colombia in 2004. A retrospective review of costs for vector control programmes carried out in rural areas included 3,084 houses surveyed for infestation with triatomine bugs and 3,305 houses sprayed with insecticide. A total of 63 patient records from 3 different hospitals were selected for a retrospective review of resource use. Consensus methodology with local experts was used to estimate care seeking behaviour and to complement observed data on utilisation. Findings: The mean cost per house per entomological survey was $4.4 ( in US$ of 2004), whereas the mean cost of spraying a house with insecticide was $27. The main cost driver of spraying was the price of the insecticide, which varied greatly. Treatment of a chronic Chagas disease patient costs between $46.4 and $7,981 per year in Colombia, depending on severity and the level of care used. Combining cost and utilisation estimates the expected cost of treatment per patient-year is $1,028, whereas lifetime costs averaged $11,619 per patient. Chronic Chagas disease patients have limited access to healthcare, with an estimated 22% of patients never seeking care. Conclusion: Chagas disease is a preventable condition that affects mostly poor populations living in rural areas. The mean costs of surveying houses for infestation and spraying infested houses were low in comparison to other studies and in line with treatment costs. Care seeking behaviour and the type of insurance affiliation seem to play a role in the facilities and type of care that patients use, thus raising concerns about equitable access to care. Preventing Chagas disease in Colombia would be cost-effective and could contribute to prevent inequalities in health and healthcare.
引用
收藏
页数:11
相关论文
共 33 条
[1]   Comparison of intervention strategies for control of Triatoma dimidiata in Nicaragua [J].
Acevedo, F ;
Godoy, E ;
Schofield, CJ .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2000, 95 (06) :867-871
[2]  
AKHAVAN D, 1996, ANALISE CUSTO EFECTI, P37
[3]   A cost-benefit analysis of Chagas disease control in north-western Argentina [J].
Basombrío, MA ;
Schofield, CJ ;
Rojas, CL ;
del Rey, EC .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1998, 92 (02) :137-143
[4]  
*BITR AS EC SA ESA, 2001, EV REESTR PROC ESTR
[5]   Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: The example of Chagas disease [J].
Castillo-Riquelme, Marianela ;
Chalabi, Zaid ;
Lord, Joanne ;
Guhl, Felipe ;
Campbell-Lendrum, Diarmid ;
Davies, Clive ;
Fox-Rushby, Julia .
JOURNAL OF HEALTH ECONOMICS, 2008, 27 (02) :405-426
[6]   RESULT OF A 1ST STEP TOWARD COMMUNITY-BASED SURVEILLANCE OF TRANSMISSION OF CHAGAS-DISEASE WITH APPROPRIATE TECHNOLOGY IN RURAL-AREAS [J].
CHUIT, R ;
PAULONE, I ;
WISNIVESKYCOLLI, C ;
BO, R ;
PEREZ, AC ;
SOSASTANI, S ;
SEGURA, EL .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1992, 46 (04) :444-450
[7]  
Drummond M., 2015, METHODS EC EVALUATIO, V4
[8]  
ESCOBAR M, 2005, HLTH SECTOR REFORM C
[9]   The use of consensus methods and expert panels in pharmacoeconomic studies - Practical applications and methodological shortcomings [J].
Evans, C .
PHARMACOECONOMICS, 1997, 12 (02) :121-129
[10]  
Gold MR, 1996, COST EFFECTIVENESS H